Asia-Pacific insulin delivery devices market is expected to reach USD 4.26 billion by 2023 from USD 2.01 billion in 2018, growing at a CAGR of 9.10% during the forecast period 2018-2023. Insulin maintains the sugar levels in the blood and essential for the people suffering from type I diabetes & type II diabetes. The development of insulin delivery devices has been encouraged from the past years. These devices are used to deliver the insulin doses via parenteral route rather than oral route of administration. Insulin delivery devices promote absorption rate of insulin into blood stream from the site of injection to execute immediate pharmacological action of insulin. Some of the majorly used insulin delivery devices such as insulin syringes, insulin pens, insulin pen needles, insulin pumps, and insulin jet injectors.
Rising number of pre-diabetic & large diabetic patient population, growing distribution networks of foreign manufacturers in this region, presence of favorable regulatory frameworks, availability of significant medical reimbursements, and growing expansions of advanced medical facilities in certain Asian countries (China & India) are driving the growth of insulin delivery devices market in Asia-Pacific region. However, low adoption of advanced diabetic technology products, high cost of the manufacturing of products, and lack awareness of diabetic patients about the advanced diabetic treatment solutions are restraining the growth of insulin delivery devices market in Asia-Pacific region.
Asia-Pacific insulin delivery devices market is segmented based on the type and application. Based on type, the market is further sub-segmented as insulin syringes, insulin pens, insulin pen needles, insulin pumps, and insulin jet injectors. Of these, insulin syringes commanded the largest share of Asia-Pacific insulin delivery devices market in 2018, whereas insulin pens segment is estimated to grow at the highest CAGR during the forecast period 2018-2023. Based on application, the market is segmented as type I diabetes and type II diabetes.
On the basis of geographical areas, Asia-Pacific insulin delivery devices market is segmented as Japan, China, India, Australia, and South Korea.
The key players in insulin delivery devices market such as, Becton, Dickinson and Company (U.S.), Sanofi (France), Novo Nordisk A/S (Denmark), Julphar (U.A.E.), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Ypsomed AG (Switzerland), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland), and Biodel Inc. (U.S.).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Introduction
5.2 Type
5.2.1 Introduction
5.2.2 Insulin Syringes
5.2.3 Insulin Pens
5.2.4 Insulin Pen Needles
5.2.5 Insulin Pumps
5.2.6 Insulin Jet Injectors
5.3 Application
5.3.1 Introduction
5.3.2 Type I Diabetes
5.3.3 Type II Diabetes
6. Geographical Analysis
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 Soth Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Sanofi (France)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Novo Nordisk A/S (Denmark)
8.3 Eli Lilly and Company (U.S.)
8.4 Biocon Ltd. (India)
8.5 Julphar (U.A.E.)
8.6 Ypsomed AG (Switzerland)
8.7 Becton, Dickinson and Company (U.S.)
8.8 Wockhardt Ltd. (India)
8.9 B. Braun Meselgen AG (Switzerland)
8.10 Biodel Inc. (U.S.)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
